glofitamab, a cd20/cd3 bispecific antibody, in the treatment of r/r dlbcl
Published 4 months ago • 338 plays • Length 7:48Download video MP4
Download video MP3
Similar videos
-
1:21
cd20/cd3 bispecific antibodies in r/r dlbcl: glofitamab and epcoritamab
-
2:21
impact of tmtv on pfs following glofitamab treatment in r/r dlbcl
-
1:48
first-in-class igm based cd20-cd3 bispecific antibody in b-cell nhl
-
5:30
glofitamab in r/r dlbcl: updated safety and efficacy data
-
2:40
phase ii study of glofitamab in patients with r/r lbcl
-
1:22
glofitamab as a soc in third-line dlbcl and its potential in earlier lines of therapy
-
6:35
the phase iii starglo trial: glofit-gemox versus r-gemox for r/r dlbcl
-
3:58
extended follow-up of glofitamab monotherapy in r/r lbcl: durability of cr and likelihood of crs
-
35:41
what is a dctl and why you need them in your colorist toolkit - episode 12
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
1:24:16
perspectives on novel antibody platforms in dlbcl
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
-
6:12
coalition: glofitamab r-chop or glofitamab pola-r-chp in patients with high-risk dlbcl
-
2:43
insights into phase i/ii study assessing fixed-duration glofitamab treatment for r/r lbcl
-
2:57
lacutamab, an anti-kir3dl2 monoclonal antibody, in the treatment of r/r ptcl
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
2:33
mitigating crs following glofitamab treatment in r/r dlbcl
-
1:45
a phase i/ii trial of glofitamab monotherapy in r/r mcl
-
7:16
changes in the classification of dlbcl
-
2:18
update on phase i/ii study of glofitamab monotherapy in r/r mcl
-
1:32
assessing the dynamics of cd8-expressing cells in patients with r/r lbcl treated with glofitamab
-
1:08
evaluating ro7443904 in combination with glofitamab in patients with r/r nhl